摘要
目的探讨埃克替尼联合最佳营养支持对非小细胞肺癌患者术后生存质量的改善效果。方法选择医院2014年3月至2015年6月收治的非小细胞肺癌术后复发患者86例,随机分为对照组和观察组,各43例。两组患者均口服盐酸埃克替尼片每次125 mg,3次/日,4周为1个疗程,共治疗3个疗程。保证对照组患者每日进食热量为自身静息状态下基础消耗的1.5倍,观察组患者在此基础上给予最佳营养支持,每天静脉滴注丙氨酰谷氨酰胺20 g和盐酸精氨酸25 g。结果对照组临床控制率为72.09%,与观察组的76.74%相近(P>0.05);治疗后,两组患者躯体日常活动、心理状态、社会功能、特意模块及总分各项指标均较治疗前有所升高(P<0.05),且观察组各指标升高程度均高于对照组(P<0.05),观察组共性症状及不良反应评分较治疗前升高(P<0.05);对照组患者血清前白蛋白(PA)、体质量指数(BMI)、血清白蛋白(ALB)、血红蛋白(Hb)均较治疗前变化不明显(P>0.05);观察组患者各指标较治疗前有所上升,且较对照组治疗后差异显著(P<0.05);两组患者不良反应发生率及严重程度相当(P>0.05)。结论非小细胞肺癌患者术后给予埃克替尼联合最佳营养支持,可显著改善患者生存质量及营养状态,且较安全,无严重不良反应。
O bjective To investigate the effect of icitinib combined with optimal nutritional support for improving life quality of patients with non-small cell lung cancer(NSCLC)after operation.M ethods Totally 86 patients with postoperative recurrence of NSCLC admitted to our hospital from March 2014 to June 2015 were randomly divided into the control group and the observation group,43 cases in each group.The two groups were treated with Icotinib Hydrochloride Tablets 125 mg each time,3 times a day,4 weeks for 1 course,the patients were treated with 3 courses of treatment.The patients in the control group received daily intake of calories for their own resting state based consumption of 1.5 times,on this basis,the patients in the observation group were given optimal nutritional support,intravenous infusion of alamyl glutamine 20 g and arginine 25 g every day.R esults The disease control rate of the control group was 72.09%,which was similar to 7 6.7 4%of the observation group(>0.0 5).After treatment,the daily activities,mental state,social function,special modules and the total score of the indicators in the two groups were higher than before trea tm e n t P<0.0 5),and those in the observation group were higher than those in the control group(<0.0 5),the scores of common symptoms and adverse reactions in the observation group were higher than those before treatm en t(P<0.05).After treatment,the indexes of prealbumin(P A),body mass index(B MI),serum albumin(ALB)and hemoglobin(H b)in the control group had no significant difference with those before treatment(P>0.0 5),but the indexes in the observation group increased compared with those before treatment,which were significantly different from those in the control group after treatment(P<0.0 5).The incidence and severity of adverse re actions were similar in the two groups(P>0.0 5).C onclusion Icitinib combined with optimal nutritional support has significant clinical effect on NSCLC patients after operation,which can significantly improve the life quality and nutritional st
作者
付伟
Fu Wei(The First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei,China 075000)
出处
《中国药业》
CAS
2018年第3期38-40,共3页
China Pharmaceuticals
基金
2014年度河北省医学科学研究重点课题计划[ZD20140476]
河北省科学技术成果[20161317]
关键词
埃克替尼
非小细胞肺癌
术后
生存质量
疾病控制率
最佳营养支持
imatinib
non-small cell lung cancer
postoperative
quality of life
disease control rate
optimal nutritional support
